Abstract: The present invention relates to certain bis[4-(2,6-dialkyl)phenol]silane derivatives which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.
Abstract: The present invention relates to certain bis[4-(2,6-dialkyl)phenol]silane derivatives which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.
Abstract: The present invention provides certain novel azadecalin amides and thioamides which are useful as inhibitors of cholesterol biosynthesis and as agents which lower total serum cholesterol in patients in need thereof.
Type:
Grant
Filed:
October 15, 1991
Date of Patent:
January 11, 1994
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Marion W. Wannamaker, William A. Van Sickle, William R. Moore
Abstract: This invention relates to novel carbocyclic adenosine compounds of the formula (1) ##STR1## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,Y.sub.3, Y.sub.7, Y.sub.8 and Y.sub.9 are each independently nitrogen or a CH group,Q is NH.sub.2, halogen or hydrogen, andZ is hydrogen, halogen, or NH.sub.2 ;or a pharmaceutically-acceptable salt thereof, and to their use as immunosuppressants.
Type:
Grant
Filed:
January 23, 1992
Date of Patent:
September 14, 1993
Assignee:
Marion Merrell Dow Inc.
Inventors:
David R. Borcherding, Carl K. Edwards, III, Ronald E. Esser, Douglas L. Cole
Abstract: The present invention relates to certain novel 8-substituted purines as selective A.sub.1 -adenosine receptor antagonists which are useful in the treatment of patients suffering from Alzheimer's disease, congestive heart failure or pulmonary bronchoconstriction.
Type:
Grant
Filed:
March 12, 1991
Date of Patent:
May 4, 1993
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Norton P. Peet, Nelsen L. Lentz, Mark W. Dudley
Abstract: This invention relates to certain 2,6-di-alkyl-4-silyl-phenols which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.
Abstract: The present invention provides novel aryloxy indanamines of the formula ##STR1## wherein n, p and q are each independently 0, 1 or 2,Y and X are each independently lower alkyl, lower alkoxy, hydroxy, CF.sub.3, halogeno or when p or q are 2 and each of the Y or each of the X groups are on adjacent aryl carbon atoms, both of the X or both of the Y groups can be taken together to form a methylenedioxy moiety,R.sub.1 and R.sub.2 are each independently hydrogen, lower alkyl, aralkyl, or R.sub.1 and R.sub.2 taken together with the nitrogen to which they are attached are pyrrolidino, morpholino, piperidino, piperazino, or 4-methylpiperazino,or an acid addition salt thereof, which are useful as antidepressants and as inhibitors of synaptic norepinephrine and serotonin uptake.
Abstract: The present invention relates to a method of lowering plasma triglycerides in a patient in need thereof comprising administering to said patient an effective hypotriglyceridemic amount of a bis(3,5-di-alkyl-4-hydroxyphenylthio)methane.
Type:
Grant
Filed:
June 19, 1990
Date of Patent:
June 16, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Simon J. T. Mao, George Ku, Richard L. Jackson
Abstract: This invention relates to a method of inhibiting the development of a cataract in a patient in need thereof comprising administering to said patient an effective cataract inhibitory amount of a bis(alkyl-substituted-4-hydroxyphenylthio)alkane analog.
Abstract: The novel organoboron reagent of the present invention is useful in the preparation of unsubstituted propargylic alcohols. This compound reacts with aldehydes and ketones cleanly to afford propargylic alcohols in excellent yields. Unsubstituted propargylic alcohols are important synthetic intermediates in the synthesis of a number of natural products. In addition, the novel organoboron reagent of the present invention also demonstrates diastereomeric selectivity when reacted with enatiomerically pure aldehydes.
Type:
Grant
Filed:
June 20, 1991
Date of Patent:
May 5, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Jonathan C. Evans, Christian T. Goralski
Abstract: The present invention relates to certain novel polyamine compounds of the formula: ##STR1## wherein Z is a saturated (C.sub.2 -C.sub.6) alkylene moiety, each R group independently is hydrogen, methyl, ethyl, or n-propyl with the provisos that both R groups cannot be hydrogen and that R is hydrogen or methyl when Z is a branched chain alkylene; or a pharmaceutically acceptable acid addition salt thereof.
Type:
Grant
Filed:
February 8, 1991
Date of Patent:
April 28, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Nellikunja Prakash, David M. Stemerick, Michael L. Edwards, Terry L. Bowlin
Abstract: The present invention relates to novel A-nor-steroid-3-carboxylic acid derivatives and to their use as inhibitors of mammalian 5.alpha.-reductase.
Type:
Grant
Filed:
September 11, 1990
Date of Patent:
March 31, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Gary A. Flynn, Philippe Bey, Thomas R. Blohm
Abstract: The present invention provides certain novel azadecalin amides and thioamides which are useful as inhibitors of cholesterol biosynthesis and as agents which lower total serum cholesterol in patients in need thereof.
Type:
Grant
Filed:
March 27, 1991
Date of Patent:
January 28, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Marion W. Wannamaker, William A. Van Sickle, William R. Moore
Abstract: This invention relates to certain novel di- and tetra-fluoro analogs of squalene and to their methods of use in lowering plasma cholesterol and in inhibiting squalene epoxidase in patients in need thereof.
Type:
Grant
Filed:
December 12, 1990
Date of Patent:
November 12, 1991
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Esa T. Jarvi, Michael L. Edwards, James R. McCarthy
Abstract: This invention relates to a method of inhibiting the development of a cataract in a patient in need thereof comprising administering to said patient an effective cataract inhibitory amount of a bis(alkyl-substituted-4-hydroxyphenylthio)alkane analog.
Abstract: The present invention relates to a liquid pharmaceutical composition comprising (a) a piperidinoalkanol in an amount of from about 2 to about 25 mM; (b) a suitable buffer, selected from the group consisting of gluconic acid buffer, lactic acid buffer, citric acid buffer and acetic acid buffer, in an amount of from about 0.001 to about 0.5 M; and (c) water in an amount of from about 5% to about 99% by weight of the composition.
Type:
Grant
Filed:
March 9, 1990
Date of Patent:
September 17, 1991
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Joseph C. Kristof, DeAnne L. Byers, Richard A. Knipstein
Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.
Abstract: The present invention relates to a method of lowering blood glucose in a patient afflicted with diabetes mellitus comprising administering to said patient a therapeutically effective glucose lowering amount of a 4,4'-bis(2,6-di-alkylphenol). The present invention also relates to a process for making 4,4'-bis(2,6-di-alkyl-phenol).
Type:
Grant
Filed:
August 21, 1990
Date of Patent:
June 4, 1991
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Keith M. Robinson, Simon J. T. Mao, Roger A. Parker, Richard L. Jackson
Abstract: This invention relates to a method of effecting immunosuppression in a patient in need thereof, comprising co-administering to said patient an effective amount of an immunosuppressive agent, wherein said immunosuppressive agent is not an ornithine decarboxylase inhibitor, and an effective amount of an ornithine decarboxylase inhibitor.